TezNewz teznewz

Real-time AI-scored market movers with ± impact ratings from -100 to +100. Latest: Symbotic Stock Plunges After Hours: Here's Why (Impact: -75). TezNewz delivers instant financial news analysis through Discord with sector-specific insights and comprehensive market intelligence.

Financial News with AI Impact Scores

Get real-time financial news with AI-powered impact analysis delivered through Discord

Today's Market Overview

TezNewz delivers AI-scored financial news with impact ratings from -100 to +100. Latest stories cover Unknown sectors. Top impact story: "Symbotic Stock Plunges After Hours: Here's Why" with -75 impact score. Join our Discord community for real-time alerts and discussions.

Latest News

Unknown -75 SYM

Symbotic Stock Plunges After Hours: Here's Why

Symbotic Inc (NASDAQ: SYM) shares fell 11.84% in after-hours trading, reaching $64.55, following the announcement of a common stock offering. The company is conducting an underwritten public offering of 10 million shares, including 6.5 million from Symbotic and 3.5 million from a SoftBank affiliate. Additionally, the underwriters have a 30-day option to purchase up to 1.5 million more shares at the public offering price. Symbotic plans to use the net proceeds from the primary offering for general corporate purposes.

Unknown +85 APLS

Apellis Pharmaceuticals Announces The The New England Journal of Medicine Published Phase 3 VALIANT Results For EMPAVELI In C3G And IC-MPGN Patients; Reports Robust And Clinically Meaningful Benefits Across All Three Key Markers Of Disease, 68% Reduction In Proteinuria, Stabilization Of Kidney Function, And Substantial Clearance Of C3 Deposits

Apellis Pharmaceuticals announced that The New England Journal of Medicine published positive Phase 3 VALIANT study results for EMPAVELI, showing a 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits in patients with C3G and IC-MPGN. The results were consistent across both adolescent and adult patients, including those with recurring C3G after transplant. EMPAVELI is noted as the first FDA-approved treatment for patients aged 12 and older with these conditions.

Unknown +75 FIVE

Five Below Stock Jumps After Q3 Earnings

Five Below Inc (NASDAQ: FIVE) reported third-quarter revenue of $1.04 billion, surpassing estimates of $983.07 million, with adjusted earnings of 68 cents per share compared to expectations of 24 cents. The company experienced a 23.1% year-over-year increase in net sales and opened 49 new stores, bringing the total to 1,907. For the fourth quarter, Five Below anticipates revenue between $1.58 billion and $1.61 billion and has raised its full-year revenue guidance to a range of $4.63 billion to $4.65 billion. Following the earnings report, Five Below's stock rose 3.86% to $169.44, exceeding its 52-week high.

Unknown +75 DSGX

Descartes Systems Gr Q3 EPS $0.50 Beats $0.45 Estimate, Sales $187.681M Beat $184.612M Estimate

Descartes Systems Group (NASDAQ: DSGX) reported Q3 earnings of $0.50 per share, exceeding the analyst estimate of $0.45 by 10.62%, and marking a 19.05% increase from $0.42 per share in the same period last year. The company also reported sales of $187.681 million, surpassing the expected $184.612 million by 1.66%, and reflecting an 11.21% increase from $168.756 million in the prior year.

Unknown -50 TTSH

Tile Shop Stockholders Approves 1-For-3,000 Reverse Split Followed Immediately By 3,000-For-1 Forward Split; Stockholders Who Hold Fewer Than 3,000 Shares Immediately Prior To The Reverse Stock Split Will Be Paid $6.60 In Cash, Without Interest, For Each Whole Share Of The Company's Common Stock Held By Them At The Effective Time Of The Reverse Stock Split

Tile Shop Holdings, Inc. (NASDAQ: TTSH) stockholders approved a 1-for-3,000 reverse stock split followed immediately by a 3,000-for-1 forward stock split. Stockholders with fewer than 3,000 shares will receive $6.60 in cash for each whole share held at the time of the reverse split. The company plans to file necessary amendments with the State of Delaware and intends to delist and deregister following regulatory processes.